Naproxen/diphenhydramine

Naproxen/diphenhydramine
Combination of
NaproxenNSAID
DiphenhydramineAntihistamine
Clinical data
Trade namesAleve PM, others
AHFS/Drugs.comAleve-PM
License data
Routes of
administration
By mouth
ATC code
Legal status
Legal status

Naproxen/diphenhydramine, sold under the brand name Aleve PM among others, is a formulation of naproxen with diphenhydramine marketed by Bayer Healthcare.[2] It is avaialble over-the-counter. The intended use of the drug is relieve pain specifically when going to sleep.[3]

Adverse effects

Women in the third trimester of pregnancy should avoid this drug because there is a risk that naproxen, like other NSAIDs, may cause premature closure of the ductus arteriosus.[3]

In October 2020, the US Food and Drug Administration (FDA) required the prescribing information to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid.[4][5] They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.[4][5]

References

  1. "Product information". health-products.canada.ca. 24 February 2016. Retrieved 18 October 2025.
  2. 1 2 "Aleve PM- diphenhydramine hydrochloride and naproxen sodium tablet, film coated". DailyMed. 6 December 2024. Retrieved 18 October 2025.
  3. 1 2 Michele TM (16 January 2014). "Summary Review for Regulatory Action: Naproxen/diphenhydramine" (PDF). U.S. Food and Drug Administration (FDA). Archived (PDF) from the original on 22 March 2016. Retrieved 21 April 2016.
  4. 1 2 "FDA Warns that Using a Type of Pain and Fever Medication in Second Half of Pregnancy Could Lead to Complications". U.S. Food and Drug Administration (FDA) (Press release). 15 October 2020. Archived from the original on 16 October 2020. Retrieved 15 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.
  5. 1 2 "NSAIDs may cause rare kidney problems in unborn babies". U.S. Food and Drug Administration (FDA). 21 July 2017. Archived from the original on 17 October 2020. Retrieved 15 October 2020. Public Domain This article incorporates text from this source, which is in the public domain.